Personal information

Countries

United States

Activities

Collapse all

Education and qualifications (4)

University of Wisconsin: Madison, Wisconsin, US

2018-07-05 to 2026-05-17 | MD (Medical Scientist Training Program)
Education
Source: Self-asserted source
Matthew Freeman

University of Wisconsin: Madison, Wisconsin, US

2018-07-05 to 2025-05-17 | PhD (Medical Scientist Training Program)
Education
Source: Self-asserted source
Matthew Freeman

University of Wisconsin–Madison: Madison, Wisconsin, US

2018-07-05 to 2022-08-31 | MS (Medical Microbiology and Immunology)
Education
Source: Self-asserted source
Matthew Freeman

University of Minnesota: Minneapolis, Minnesota, US

2014-09 to 2018-05 | Bachelor of Science
Education
Source: Self-asserted source
Matthew Freeman

Professional activities (2)

American Society for Microbiology: D.C., D.C., US

2019-05-28 to present | Student
Membership
Source: Self-asserted source
Matthew Freeman

American Medical Association: Madison, Wisconsin, US

2018-08-01 to present | Student Member
Membership
Source: Self-asserted source
Matthew Freeman

Works (4)

Duration of Time CD4/CD8 Ratio is Below 0.5 is Associated with Progression to Anal Cancer in Patients with HIV and High-Grade Dysplasia

Annals of Surgical Oncology
2023-03-04 | Journal article
DOI: 10.1245/s10434-023-13213-z
Part of ISSN: 1068-9265
Part of ISSN: 1534-4681
Contributors: Aos Karim; Matthew J. Freeman; Qiuyu Yang; Glen Leverson; Linda Cherney-Stafford; Rob Striker; Cristina B. Sanger
Source: Self-asserted source
Matthew Freeman

Club cell TRPV4 as a damage sensor driving lung allergic inflammation

[]
2019-09-19 | Journal article
DOI: 10.1101/773382
Source: Self-asserted source
Matthew Freeman

Retinoblastoma cells activate the AKT pathway and are vulnerable to the PI3K/mTOR inhibitor NVP-BEZ235

Oncotarget
2017-06-13 | Journal article
DOI: 10.18632/oncotarget.16970
Part of ISSN: 1949-2553
Source: Self-asserted source
Matthew Freeman

Loss of UHRF2 expression is associated with human neoplasia, promoter hypermethylation, decreased 5-hydroxymethylcytosine, and high proliferative activity

Oncotarget
2016-11-15 | Journal article
DOI: 10.18632/oncotarget.12583
Part of ISSN: 1949-2553
Source: Self-asserted source
Matthew Freeman
How many people are using ORCID?